U.S. Food and Drug Administration (FDA) Advisories
December 14, 2016: General Anesthetic and Sedation Drugs: FDA is warning that repeated or lengthy use of general anesthetic and sedation drugs during surgeries or procedures in children younger than 3 years or in pregnant women during their third trimester may affect the development of children's brains.
Consistent with animal studies, recent human studies suggest that a single, relatively short exposure to general anesthetic and sedation drugs in infants or toddlers is unlikely to have negative effects on behavior or learning. However, further research is needed to fully characterize how early life anesthetic exposure affects children's brain development.
To better inform the public about this potential risk, FDA is requiring warnings to be added to the labels of general anesthetic and sedation drugs (see List of General Anesthetic and Sedation Drugs Affected by this Label Change). FDA will continue to monitor the use of these drugs in children and pregnant women and will update the public if additional information becomes available.
December 12, 2016: Pioglitazone-containing Medicines: As a result of an updated review, the FDA has concluded that use of the type 2 diabetes medicine pioglitazone (Actos, Actoplus Met, Actoplus Met XR, Duetact, Oseni) may be linked to an increased risk of bladder cancer. The labels of pioglitazone-containing medicines already contain warnings about this risk, and FDA has approved label updates to describe the additional studies reviewed.
Registration is now open for the Evidence-based Guidelines Affecting Policy, Practice and Stakeholders (E-GAPPS III) Conference. It will be held March 20-21, 2017 at The New York Academy of Medicine. The event is sponsored by the Guidelines International Network North America (G-I-N NA) and NYAM's Section on Evidence Based Health Care (SEBHC). The conference is titled "Beyond Implementation: Are Clinical Guidelines Improving Healthcare Quality?"
AHRQ Announces Funding Opportunity for Developing Measures of Shared Decisionmaking
A new funding opportunity announcement from AHRQ solicits applications for research projects to develop, test and evaluate measures of shared decisionmaking for research conducted in clinical settings. Shared decisionmaking is a collaborative process in which patients and members of their clinical team make health care decisions that are informed by scientific evidence as well as patients' values and preferences. Each project is expected to produce valid and reliable measures of shared decisionmaking, along with instructions for implementing the measures and documentation on the development, testing and evaluation of the measures. The maximum cost for each project is $500,000 per year and $1.5 million for up to three years.
How to Participate
Submit Guidelines: Visit our Submit Guidelines page for information on how to submit your organization's guidelines.
Suggest a Guideline for Possible Inclusion: Submit your suggestions for evidence-based clinical practice guidelines that you would like to see included in NGC.